ALL AGREEMENT STATES, VERMONT

NOTIFICATION OF ISSUANCE OF GERMANIUM-68/GALLIUM-68 PHARMACEUTICAL GRADE GENERATORS LICENSING GUIDANCE (STC-19-048)

Purpose: To inform the Agreement States that updated Germanium-68/Gallium-68 Pharmaceutical Grade Generators Licensing Guidance was published in July 25, 2019.

Background: The U.S. Nuclear Regulatory Commission (NRC) current licensing guidance under Title 10 Code of Federal Regulations (CFR) 35.1000 for Germanium-68/Gallium-68 generators [Ge-68/Ga-68 generators] (Revision 1) was issued on July 13, 2017, and can be found in NRC’s Agencywide Documents Access Management System (ADAMS) (Accession No. ML17075A488). At that time, the only Ge-68/Ga-68 generator approved by the U.S. Food and Drug Administration (FDA) and available on the market was the Eckert and Ziegler GalliaPharm® generator.

Discussion: Now that additional Ge-68/Ga-68 generators (IREs [Institute of Radio Elements] Galli Eo™ generator and others) are becoming commercially available, the Ge-68/Ga-68 generator licensing guidance has been revised to eliminate reference to any specific generator manufacturer or product. All sections of this guidance apply to both medical licensee and commercial nuclear pharmacy licensee use of this generator unless otherwise specified. This guidance does not apply to licensees or applicants that will receive unit or bulk doses of Gallium-68 (Ga-68) radiopharmaceuticals. This guidance provides applicants with an acceptable means of satisfying the requirements for a license for the use of Ge-68/Ga-68 generators to prepare Ga-68 radiopharmaceuticals. It is not intended to be the only means of satisfying the requirements for a license.

This licensing guidance revision is available online at http://www.nrc.gov/materials/miau/med-use-toolkit.html.
If you have any questions regarding this correspondence, please contact me at 301-415-5804 or the individual named below:

POINT OF CONTACT: Said Daibes, PhD  
E-MAIL: Said.Daibes@nrc.gov
TELEPHONE: (301) 415-6863

/RA/

Paul Michalak, Chief  
State Agreement and Liaison Programs  
Division of Materials Safety, Security, State and Tribal Programs  
Office of Nuclear Material Safety and Safeguards

Enclosure:  
Germanium-68/Gallium-68 Pharmaceutical Grade Generators Licensing Guidance
Germanium-68/Gallium-68 Pharmaceutical Grade Generators Licensing Guidance

July, 2019

U.S. Nuclear Regulatory Commission
Contact: Said Daibes Figueroa
(301) 415-6863
MedicalQuestions.Resource@nrc.gov
**Table of Contents**

1. 10 CFR 35.1000 Use...................................................................................................1
2. Commercial Nuclear Pharmacy Use under 10 CFR 30.33............................................1
3. Licensing Guidance.....................................................................................................1
4. General........................................................................................................................2
   4.1 Use of Ge-68/Ga-68 Generator to Prepare Ga-68 Radiopharmaceuticals for Imaging and Localization Studies.................................................................................2
   4.2 Radionuclides, Form, Possession Limits, and Purpose of Use .................................3
   4.3 Facility Address and Description [10 CFR 30.33(a)(2) and 10 CFR 35.12(b)(1)] ..3
   4.4 Authorized Individuals [10 CFR 30.33(a)(3) and 10 CFR 35.12(b)(1)].................4
5. License Commitments..................................................................................................5
7. Notes to Licensees......................................................................................................7
   7.1 Labeling ...............................................................................................................7
   7.2 Assay of Dosages............................................................................................  7
   7.3 Waste Disposal...................................................................................................7
      7.3.1 Eluate Disposal..........................................................................................7
      7.3.2 Returning Generators to the Manufacturer/Distributor...............................8
   7.4 Financial Assurance for Decommissioning...........................................................8
8. Inspection Frequency...................................................................................................9
9. Program Code.................................................................................................................9
This guidance is specific to the use of Germanium-68/Gallium-68 (Ge-68/Ga-68) pharmaceutical grade generators. All sections of this guidance apply to both medical licensee and commercial nuclear pharmacy licensee use of this generator unless otherwise specified. This guidance does not apply to licensees or applicants that will receive unit or bulk doses of Gallium-68 (Ga-68) radiopharmaceuticals. These licensees and applicants will be regulated under Title 10 of the Code of Federal Regulations (10 CFR) 35.200.

1. **10 CFR 35.1000 Use**

Ga-68 is a positron emitter that allows Ga-68 radiopharmaceuticals to be imaged using positron emission tomography (PET). Ga-68 can be produced in a cyclotron or by the elution of a Ge-68/Ga-68 generator.

Ge-68/Ga-68 generators are similar to conventional molybdenum-99/technetium-99m (Mo-99/Tc-99m) and strontium-82/rubidium-82 (Sr-82/Rb-82) generators, which are regulated under 10 CFR 35.200. Like Mo-99/Tc-99m and Sr-82/Rb-82 generators, breakthrough of the parent radionuclide is possible when eluting the generator. This could lead to Germanium-68 (Ge-68) contaminating the Ga-68 radiopharmaceutical and potentially causing an unnecessarily high radiation exposure to patients. 10 CFR 35.204 provides permissible concentration limits for parent radionuclides for Mo-99/Tc-99m and Sr-82/Rb-82 generators to limit such exposure, but no such limit is specified for Ge-68/Ga-68 generators. Therefore, the use of a Ge-68/Ga-68 generator to prepare Ga-68 radiopharmaceuticals for imaging and localization studies is regulated under 10 CFR 35.1000, \(^1\) "Other Medical Uses of Byproduct Material or Radiation from Byproduct Material."

2. **Commercial Nuclear Pharmacy Use under 10 CFR 30.33**

Ga-68 radiopharmaceuticals may be prepared at commercial nuclear pharmacies and then provided to medical licensees for their use. Since the potential for Ge-68 breakthrough exists, the U.S. Nuclear Regulatory Commission (NRC) will require appropriate commitments from applicants that use these generators prior to granting authorization to possess and use the generators to produce Ga-68. In accordance with 10 CFR 30.33, “General requirements for issuance of specific licenses,” a commercial nuclear pharmacy will have to apply for a license or amend its license to be authorized to possess and use a Ge-68/Ga-68 generator.

3. **Licensing Guidance**

Applicants and licensees may voluntarily use this guidance to demonstrate compliance with the underlying NRC regulations. Methods that differ from those described in this guidance may be deemed acceptable if they provide sufficient basis and information for the NRC staff to conclude that the proposed alternative demonstrates compliance with the appropriate NRC regulations.

This guidance provides applicants with an acceptable means of satisfying the requirements for a license for the use of the Ge-68/Ga-68 generator to prepare Ga-68 radiopharmaceuticals and is not intended to be the only means of satisfying the requirements for a license. While the Ge-68/Ga-68 generators are similar to conventional molybdenum-99/technetium-99m and strontium-82/rubidium-82 generators, which are regulated under 10 CFR 35.200. Like Mo-99/Tc-99m and Sr-82/Rb-82 generators, breakthrough of the parent radionuclide is possible when eluting the generator. This could lead to Germanium-68 (Ge-68) contaminating the Ga-68 radiopharmaceutical and potentially causing an unnecessarily high radiation exposure to patients. 10 CFR 35.204 provides permissible concentration limits for parent radionuclides for Mo-99/Tc-99m and Sr-82/Rb-82 generators to limit such exposure, but no such limit is specified for Ge-68/Ga-68 generators. Therefore, the use of a Ge-68/Ga-68 generator to prepare Ga-68 radiopharmaceuticals for imaging and localization studies is regulated under 10 CFR 35.1000, \(^1\) "Other Medical Uses of Byproduct Material or Radiation from Byproduct Material."

\(^1\) This regulation at 10 CFR 35.1000 is designated as Compatibility Category D. Agreement States are not required to adopt these regulations for purposes of compatibility.
The 68/Ga-68 generator is not regulated under 10 CFR 35.200, some sections in this guidance include guidance that is analogous to provisions in 10 CFR 35.200. The applicant must submit the information required by 10 CFR 30.33 and 35.12, as described below. The applicant should submit additional information and commitments requested below or may, unless the information is specifically required by regulation, submit alternative information for review by the NRC staff to make a licensing determination. The commitments incorporated into the applicant’s license by license condition will be reviewed during routine inspections.

Applicants are reminded that licenses issued pursuant to 10 CFR 35.1000 must still meet the general requirements in 10 CFR Part 35, Subparts A, B, C, L, and M, except as specified in this guidance. Additionally, applicants must meet the applicable requirements of 10 CFR Parts 19, 20, and 30.

4. **General**

4.1 **Use of Ge-68/Ga-68 Generator to Prepare Ga-68 Radiopharmaceuticals for Imaging and Localization Studies**

Medical use applicants should follow 10 CFR 35.200(b). A medical licensee may prepare its own Ga-68 radiopharmaceuticals using a Ge-68/Ga-68 generator. The licensee may use Ga-68 radiopharmaceuticals for imaging and localization studies that are prepared by either:

1) an authorized nuclear pharmacist (ANP); or

2) a physician who is an Authorized User (AU) and who meets the requirements specified in 10 CFR 35.290, or 10 CFR 35.390 and 10 CFR 35.290(c)(1)(ii)(G); or

3) an individual under the supervision, as specified in 10 CFR 35.27, of either
   a. an ANP, or
   b. a physician who is an AU who meets the requirements specified in 10 CFR 35.290, or 10 CFR 35.390 and 10 CFR 35.290(c)(1)(ii)(G).

Medical licensees that prepare their own Ga-68 radiopharmaceuticals using a Ge-68/Ga-68 generator may use these radiopharmaceuticals in clinical practice if utilizing an FDA-approved kit for radiolabeling, or in research in accordance with a Radioactive Drug Research Committee-approved application or an Investigational New Drug (IND) protocol accepted by the FDA.

Licensees are reminded that the use of the Ge-68/Ga-68 generator is regulated under 10 CFR 35.1000 and the radiopharmaceuticals prepared using this generator are regulated under 10 CFR 35.200. Note that licensees that use Ga-68 radiopharmaceuticals for medical imaging and localization studies will be regulated under 10 CFR 35.200, as well. This is true whether the Ga-68 is generator- or cyclotron-produced. AUs who use Ga-68 radiopharmaceuticals must meet training requirements.
4.2 Radionuclides, Form, Possession Limits, and Purpose of Use

The applicant shall identify the radionuclides, chemical/physical form, requested maximum possession limit, and purpose of use. The NRC Form 313 may be used to submit this information. For example, the following provides the format for an acceptable request:

For medical licensees:

<table>
<thead>
<tr>
<th>Radionuclides (Form 313 Item 5)</th>
<th>Ge-68/Ga-68 as permitted by 10 CFR 35.1000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical/Physical Form (Form 313 Item 5)</td>
<td>Any</td>
</tr>
<tr>
<td>Maximum Possession Limit (Form 313 Item 5)</td>
<td>100 mCi of Ge-68 100 mCi of Ga-</td>
</tr>
<tr>
<td>Authorized Use (Form 313 Item 6)</td>
<td>For 10 CFR 35.1000 use of the Ge-68/Ga-68 generator to prepare Ga-68 radiopharmaceuticals for imaging and localization studies. Any imaging and localization study permitted by 10 CFR 35.200.</td>
</tr>
</tbody>
</table>

For commercial nuclear pharmacy licensees:

<table>
<thead>
<tr>
<th>Radionuclides (Form 313 Item 5)</th>
<th>Ge-68 Ga-68</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical/Physical Form (Form 313 Item 5)</td>
<td>Any</td>
</tr>
<tr>
<td>Maximum Possession Limit (Form 313 Item 5)</td>
<td>100 mCi of Ge-68 100 mCi of Ga-68</td>
</tr>
<tr>
<td>Authorized Use (Form 313 Item 6)</td>
<td>For use of the Ge-68/Ga-68 generator to prepare Ga-68 radiopharmaceuticals for imaging and localization studies. For preparation and distribution of radioactive drugs in accordance with 10 CFR 32.72 and radiochemicals for non-medical use to authorized</td>
</tr>
</tbody>
</table>

4.3 Facility Address and Description [10 CFR 30.33(a)(2) and 10 CFR 35.12(b)(1)]

Provide an address of use and submit a facility diagram and description of the location(s) where the generator will be received, used, and stored. If applicable, provide a
description of imaging rooms and patient waiting rooms and include shielding information and calculations appropriate for the PET imaging facility. American Association of Physicists in Medicine Task Group 108, “PET and PET/CT Shielding Requirements,” provides guidance on how to design a PET imaging facility and perform associated shielding calculations. Additional information can also be found in NUREG 1556, Volume 9.

4.4 Authorized Individuals [10 CFR 30.33(a)(3) and 10 CFR 35.12(b)(1)]

The NRC has determined that individuals meeting the guidance provided below will be considered qualified and authorized to use Ge-68/Ga-68 generators to elute Ga-68. Applicants may also submit alternative training and experience commitments to be reviewed on a case-by-case basis by the NRC staff. The alternative information should include an explanation of why the applicant believes the alternative information demonstrates that an individual is qualified to be an AU or ANP.

Applicants and licensees should identify each AU or ANP and provide documentation of his/her training and experience in the use of Ge-68/Ga-68 generators. NRC Form 313A (AUD), “Authorized User Training and Experience and Preceptor Attestation for uses defined under 10 CFR 35.100, 35.200 and 35.500,” and NRC Form 313A (ANP), “Authorized Nuclear Pharmacist Training and Experience and Preceptor Attestation [10 CFR 35.55]” or other formats may be used to document this training and experience.

The individual will be considered qualified for use of a Ge-68/Ga-68 generator if the licensee demonstrates that the individual meets the following:

1) Is identified as an **authorized user** on (1) a NRC or Agreement State medical use license, or (2) a medical use permit issued by an NRC or Agreement State broad scope licensee or master material licensee, or a master material license permittee of broad scope for medical uses in 10 CFR 35.200 or 10 CFR 35.300 provided the authorized user successfully completed the requirements in 10 CFR 35.290(c)(1)(ii)(G);

   **OR**

2) Is identified as an **authorized nuclear pharmacist** on one of the following that authorizes medical use or the practice of nuclear pharmacy: a NRC or Agreement State license, or a permit issued by an NRC or Agreement State broad scope licensee or master material license permit, or by a master material license permittee of broad scope, or is identified as an authorized nuclear pharmacist by a commercial nuclear pharmacy authorized to list its own authorized nuclear pharmacist;

   **OR**

3) Meets the requirements in:

   a. 10 CFR 35.290 or 10 CFR 35.390 with training and experience for 10 CFR 35.290(c)(1)(ii)(G), or

   b. 10 CFR 35.55, “Training for an authorized nuclear pharmacist,”
AND

4) Meets the requirements in 10 CFR 35.59 for recentness of training, if applicable.

Other individuals, working under supervision of an AU or ANP described above, are authorized to elute the Ge-68/Ga-68 generator to prepare Ga-68 radiopharmaceuticals for imaging and localization studies in accordance with 10 CFR 35.27.

5. **License Commitments**

As noted above, applicants and licensees may voluntarily use these commitments to demonstrate compliance with NRC regulations. Methods that differ from those described here may be deemed acceptable if they provide sufficient basis and information for the NRC staff to conclude that the proposed alternative demonstrates compliance with the appropriate NRC regulations.

Under this guidance, an applicant requesting authorization for a Ge-68/Ga-68 generator should commit to the following:

- Providing instructions and/or training on the manufacturer’s procedures to all individuals involved in Ge-68/Ga-68 generator use, commensurate with the individual’s duties to be performed;

- Not opening, breaching, or physically modifying the Ge-68/Ga-68 generator in any way;

- Following the manufacturer’s procedures, including: generator set-up; generator elution; Ge-68 breakthrough testing and frequency when in use; and final disposition;

- Eluting the generator in accordance with the manufacturer’s stated frequency and procedures to minimize the concentration of Ge-68 in the eluate;

- Not using an expired generator for preparation of materials that will be administered to patients or human research subjects;

- Only using a generator that has a clearly marked expiration date;

- After installation, performing the conditioning procedure following the manufacturer’s instructions properly disposing of the conditioning eluates prior to the first use of eluate for testing or human use;

- Developing and implementing written procedures for the determination of breakthrough that will detect whether the eluate exceeds the manufacturer’s recommended breakthrough limit;

- During the course of breakthrough testing, if the eluate exceeds the manufacturer’s breakthrough limits, the eluate will not be distributed or administered to a patient or
human research subject;

- Maintaining a record of the breakthrough tests for at least 3 years. These tests should include the ratio of the measured activity of Ge-68 per Ga-68 corrected for the time of elution, time and date of the elution, time and date of the measurement, and the name of the individual who made the measurement;

- Notifying by telephone the NRC Operations Center (301-816-5100) and the manufacturer/distributor of the generator within 7 calendar days after discovery of a generator that is unable to meet the manufacturer’s stated Ge-68 breakthrough limits. A failed generator effective date will be when the breakthrough calculation was performed, which should be no more than 7 days from the date of the previous breakthrough calculation;

- Include in the report to the NRC Operations Center the manufacturer, model number, and serial number (or lot number) of the generator; the results of the measurement; the date of the measurement; whether dosages were administered to patients or human research subjects; when the manufacturer/distributor was notified; and the action taken;

- Sending a written report to the appropriate NRC Regional Office within 30 days after discovery of a generator that is unable to meet the manufacturer’s stated breakthrough limits of Ge-68 on multiple occasions rendering the generator unusable in human patients and research subjects.

- Include in the written report the action taken by the licensee; probable cause and assessment of failure in the licensee's equipment, procedures or training that contributed to the excessive readings if an error occurred in the licensee’s breakthrough determination, and the information in the telephone report made as described above;

- Conduct surveys of all areas of licensed material use, including the generator storage and kit preparation areas, for contamination each day of use; and

- Developing and implementing written emergency procedures for leaking or damaged generators;

6. **Radiation Protection Program Changes [10 CFR 35.26]**

An applicant initially applying for authorization for use of a Ge-68/Ga-68 generator for preparation of Ga-68 radiopharmaceuticals for imaging and localization studies may request to incorporate into its license a change process similar to 10 CFR 35.26. Such a change process can allow some future changes to radiation safety programs without the need to request a license amendment. One example of an acceptable radiation protection program change process under this guidance would include the following elements:

1) The revision does not require a license amendment under 10 CFR 35.13;

2) The revision is based upon NRC’s current guidance for use of the Ge-68/Ga-68
generator to prepare Ga-68 radiopharmaceuticals for imaging and localization studies under 10 CFR 35.1000 posted on the NRC Medical Uses Licensee Toolkit;

3) The revision has been reviewed and approved by the licensee’s Radiation Safety Officer and management;

4) The affected individuals are instructed on the revised program before the change is implemented;

5) The licensee shall retain a record of each change for 5 years; and

6) The record will include a copy of the current guidance for use of the Ge-68/Ga-68 generator to prepare Ga-68 radiopharmaceuticals for imaging and localization studies under 10 CFR 35.1000, the old procedure, the new procedure, the effective date of the change, and the signature of the licensee management representative who reviewed and approved the change.

If approved, these conditions for use of updated guidance will be incorporated as license conditions in the licensee’s license.

7. **Notes to Licensees**

7.1 **Labeling**

Syringes and unit dosages must be labeled in accordance with 10 CFR 35.69 for medical licenses and 10 CFR 32.72(a)(4) for commercial nuclear pharmacy licenses.

7.2 **Assay of Dosages**

Assay each patient dosage in the dose calibrator (or instrument) before administering it (10 CFR 35.63). Do not use a dosage if it does not fall within the prescribed dosage range or if it varies more than ±20 percent from the prescribed dosage, except as approved by an AU.

7.3 **Waste Disposal**

7.3.1 **Eluate Disposal**

Due to breakthrough, the eluate may contain small amount of Ge-68 activity, which has a half-life of greater than 120 days (the half-life of Ge-68 is 270.8 days). Depending on the activity of Ge-68, composition of the waste, and state, local, and federal regulations, the licensee may need to:

- Dispose the waste in accordance with 10 CFR 20.2003; or
- Transfer the waste to an authorized recipient.

Additional information can also be found in reference IN 94-07, "Solubility Criteria
7.4 Financial Assurance for Decommissioning

In accordance with 10 CFR Section 30.35, “Financial Assurance and Recordkeeping for Decommissioning,” applicants must have a Decommissioning Funding Plan (DFP) to obtain a license to possess Ge-68/Ga-68 generators. In a July 29, 2016 memorandum (Agencywide Documents Access and Management Accession No. ML16082A415) the Director of the NRC Office of Nuclear Material Safety and Safeguards delegated to the NRC’s Regional Administrators the authority to grant an exemption to the DFP requirement for 10 CFR Part 30 possession and use of Ge-68/Ga-68 generators under certain circumstances.

The revised memorandum issued on July 13, 2017 (Accession No. ML17075A487) specifically authorizes Regional Administrators to issue an exemption, when requested, only for Ge-68/Ga-68 generators and only if a legally binding agreement is in place for the licensee to return the generators to the manufacturer or distributor when the generators are no longer used. Licensees must continue to provide FA in amounts described in the exemption memorandum pursuant to NRC DFP requirements. Licensees possessing one or two Ge-68/Ga-68 generators (50 to 100 mCi of material) must provide for financial assurance for decommissioning in the amount of $225,000.00. Licensees possessing more than 2 generators (>100 mCi) must provide financial assurance for decommissioning in the amount of $1,125,000.00.

The legally binding agreement for the return of the generator(s), in order for the DFP exemption to apply, should contain terms that include: (1) a commitment that the generator recipient shall return the generator to the manufacturer or distributor; (2) a commitment that the generator manufacturer or distributor shall accept receipt of the
returned generator; (3) that conditions for the manufacturer or distributor’s receipt of
the generator are reasonable and facilitate the return of the generator; (4) that the
manufacturer or distributor is authorized to possess the radioactive material; (5) that
the parties to the agreement are the recipient(s) of the generators and the
manufacturer or distributor(s) of the generators; (6) that the agreement is signed by
persons authorized to enter into legally binding agreements on behalf of the
recipient(s) and manufacturer or distributor(s); and (7) that the agreement is dated.

Licensees and applicants who wish to request such an exemption should refer to the
exemption memorandum for more information.

8. **Inspection Frequency**

Medical licensees authorized to use a Ge-68/Ga-68 generator to prepare Ga-68
radiopharmaceuticals should be inspected every 5 years. Per Enclosure 1 to Inspection Manual
Chapter (IMC) 2800, licenses authorizing emerging technology in 10 CFR 35.1000 for
diagnostic use are assigned a Priority 5 inspection code.

The commercial nuclear pharmacy licensees authorized to use a Ge-68/Ga-68 generator will
be inspected every 2 years. This is the normal inspection frequency for a commercial nuclear
pharmacy in accordance with inspection manual chapter 2800.

9. **Program Code**

In accordance with IMC 2800, program codes 02121, 02201, and 02220 are for a “medical
institution – written directive not required.” The use of Ga-68 radiopharmaceuticals that are
produced using a Ge-68/Ga-68 generator under 10 CFR 35.1000 is a diagnostic use that does
not require a written directive. Therefore, the NRC regions should use program code 02121,
02201, or 02220, as applicable.

The commercial nuclear pharmacies will continue to use the program code 02500.
Paperwork Reduction Act
Statement

The information collections contained in this draft guidance are covered by the requirements of 10 CFR Parts 30 and 35, which were approved by the Office of Management and Budget (OMB), approval numbers 3150-0017, 3150-0120 and 3150-0010.

Public Protection Notification

The NRC may not conduct or sponsor, and a person is not required to respond to, a request for information or an information collection requirement unless the requesting document displays a currently valid OMB control number.
SUBJECT: GERMANIUM-68/GALLIUM 68 PHARMACEUTICAL GRADE GENERATOR LICENSING GUIDANCE

DATED: JULY 25, 2019

ADAMS Accession No: ML19106A367

<table>
<thead>
<tr>
<th>OFFICE</th>
<th>NMSS/MSEB</th>
<th>NMSS/MSEB</th>
<th>NMSS/MSEB</th>
<th>OGC</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAME</td>
<td>SDaibes</td>
<td>LDimmick</td>
<td>CEinberg</td>
<td>AGendelman</td>
</tr>
<tr>
<td>DATE</td>
<td>04/15/19</td>
<td>04/17/19</td>
<td>05/02/19</td>
<td>07/17/19</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OFFICE</th>
<th>NMSS/MSST</th>
</tr>
</thead>
<tbody>
<tr>
<td>NAME</td>
<td>AKock</td>
</tr>
<tr>
<td>DATE</td>
<td>07/25/19</td>
</tr>
</tbody>
</table>